株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

精神医学関連の各種提携契約:契約条件・合意内容

Global Psychiatry Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 238157
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
精神医学関連の各種提携契約:契約条件・合意内容 Global Psychiatry Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年09月01日 ページ情報: 英文
概要

当レポートでは、精神医学関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 精神医学関連の各種契約の動向

  • イントロダクション
  • 過去数年における精神医学関連の提携
  • 大手製薬会社による契約活動
  • 精神医学関連の事業に積極的でない大手製薬会社
  • 精神医学関連の提携:契約タイプ別
  • 精神医学関連の提携:産業部門別
  • 精神医学関連の提携:開発ステージ別
  • 精神医学関連の提携:技術タイプ別
  • 平均契約期間
  • 前払い金
  • 目標達成報酬
  • ロイヤリティ料率、など

第3章 主要契約

  • イントロダクション
  • 主要契約:取引額別
  • 大手製薬会社のかかわる主要契約

第4章 大手製薬会社による契約

  • 企業プロファイル

第5章 契約ディレクトリ

  • イントロダクション
  • 企業別:A-Z
  • 契約タイプ別
    • 資産購入
    • 大手によるアウトライセンシング
    • 共同開発
    • 共同R&D
    • サービス契約
    • 共同プロモーション
    • CRADA
    • 開発
    • 流通販売
    • 評価
    • 譲与
    • ジョイントベンチャー
    • ライセンシング
    • 製造
    • マーケティング
    • 材料転移
    • オプション
    • プロモーション
    • 研究
    • 和解関連
    • スピンアウト
    • 供給
    • 技術移転
  • 開発ステージ別
    • 創薬
    • 前臨床
    • フェーズI
    • フェーズII
    • フェーズIII
    • 申請登録
    • 市販
  • 技術タイプ別
    • アジュバント
    • 解析
    • 動物モデル
    • アッセイ
    • バイオディフェンス
    • バイオインフォマティクス
    • 生物学的化合物
    • バイオマーカー
    • バイオマテリアル
    • バイオプロセッシング
    • バイオシミラー/バイオベター
    • 血液製剤
    • 細胞培養
    • 細胞治療
    • 臨床検査
    • 診断(コンパニオン)
    • デバイス
    • 診断
    • 創薬ツール
    • DNAプローブ
    • ドラッグデリバリー
    • 実現技術
    • エピジェネティクス
    • 機器
    • 設備
    • 遺伝子治療
    • ゲノミクス
    • グリコミクス
    • イメージング
    • インプラント
    • インビトロモデル
    • マイクロアレイ
    • モノクローナル抗体ナノテクノロジー、など
  • 適応症別
    • 精神病
    • 不安障害
    • 全般性不安障害
    • パニック障害
    • PTSD
    • 注意欠陥多動障害
    • 双極性障害
    • 慢性疲労症候群
    • 認知障害
    • 痴呆
    • アルツハイマー
    • レビー小体型認知症
    • 自閉症
    • 躁病
    • 強迫性障害
    • 精神分裂性
    • 睡眠障害

第6章 提携機会

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2204

The ‘Global Psychiatry Partnering 2010-2016: Deal trends, players and financials ’report provides comprehensive understanding and unprecedented access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Psychiatry Partnering 2010 to 2016’ provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Psychiatry partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Psychiatry partnering agreement structure
  • Psychiatry partnering contract documents
  • Top Psychiatry deals by value
  • Most active Psychiatry dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Psychiatry deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Psychiatry deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2010. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report scope

‘Global Psychiatry Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Psychiatry trends and structure of deals entered into by leading companies worldwide.

‘Global Psychiatry Partnering 2010 to 2016’ includes:

  • Trends in Psychiatry dealmaking in the biopharma industry since 2010
  • Analysis of Psychiatry deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Psychiatry deal contract documents
  • Comprehensive access to over 3500 Psychiatry deal records
  • The leading Psychiatry deals by value since 2010
  • Most active Psychiatry dealmakers since 2010

The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

In ‘Global Psychiatry Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Psychiatry Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 600 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Psychiatry Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Psychiatry deal trends since 2010
  • Access Psychiatry deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Psychiatry partner companies
  • Comprehensive access to over 750 links to actual Psychiatry deals entered into by the world's biopharma companies
  • Indepth review of Psychiatry deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Psychiatry opportunities
  • Uncover companies actively partnering Psychiatry opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Psychiatry dealmaking

  • 2.1. Introduction
  • 2.2. Psychiatry partnering over the years
  • 2.3. Psychiatry partnering by deal type
  • 2.4. Psychiatry partnering by industry sector
  • 2.5. Psychiatry partnering by stage of development
  • 2.6. Psychiatry partnering by technology type
  • 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 -Financial deal terms for Psychiatry partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Psychiatry partnering
  • 3.3. Psychiatry partnering headline values
  • 3.4. Psychiatry deal upfront payments
  • 3.5. Psychiatry deal milestone payments
  • 3.6. Psychiatry royalty rates

Chapter 4 - Leading Psychiatry deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Psychiatry partnering
  • 4.3. List of most active dealmakers in Psychiatry
  • 4.4. Top Psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

  • 5.1. Introduction
  • 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Psychiatry therapeutic target

Appendices

  • Appendix 1 - Directory of Psychiatry deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Psychiatry deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Psychiatry deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Psychiatry deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Psychiatry partnering since 2010
  • Figure 2: Psychiatry partnering by deal type since 2010
  • Figure 3: Psychiatry partnering by industry sector since 2010
  • Figure 4: Psychiatry partnering by stage of development since 2010
  • Figure 5: Psychiatry partnering by technology type since 2010
  • Figure 6: Psychiatry partnering by indication since 2010
  • Figure 7: Psychiatry deals with a headline value
  • Figure 8: Psychiatry deals with upfront payment values
  • Figure 9: Psychiatry deals with milestone payment
  • Figure 10: Psychiatry deals with royalty rates
  • Figure 11: Active Psychiatry dealmaking activity- 2010 to 2016
  • Figure 12: Top Psychiatry deals by value since 2010
Back to Top